Future studies should address the detailed impact of HDC/LD-IL-2 in subgroups of AML, including efficacy according to MRD status after completed chemotherapy and effects of HDC/LD-IL-2 on the switch of MRD to positivity or negativity. Here, IL2 is linked to acute myeloid leukemia.